2024 / 06

Next Paper
DOI: 10.24075/brsmu.2024.058
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Strains of Mycobacterium tuberculosis with mutations in gyrA differ in their level of competitive fitness

Andreevskaya SN1, Smirnova TG1, Chernousova LN1, Larionova EE1, Sevastyanova EV1, Ustinova VV1, Kiseleva EA1, Ergeshov A1,2
About authors

1 Central Tuberculosis Research Institute, Moscow, Russia

2 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

Correspondence should be addressed: Sophia Nikolayevna Andreevskaya
Yauzskaya Alley, 2 p. 1A, Moscow, 107564, Russia; ur.liam@aifosdna

About paper

Funding: the study was conducted under the State assignment of FGBNU ‘CNIIT’ No. NIOCTR 122041100246-3 ‘Interspecies and intraspecies polymorphism of mycobacteria in patients with tuberculosis and mycobacteriosis in the presence of specific therapy’.

Author contribution: Chernousova LN, Ergeshov A — development of the research design; Ustinova VV, Kiseleva EA — conducting the experiment; Smirnova TG — conducting the experiment, analyzing the obtained data; Larionova EE — analyzing the obtained data; Sevastyanova EV — review of publications on the topic of the research; Andreevskaya SN — analyzing the obtained data, writing the manuscript.

Received: 2024-11-05 Accepted: 2024-11-29 Published online: 2024-12-19
|
  1. Eldholm V, Balloux F. Antimicrobial Resistance in Mycobacterium tuberculosis: The Odd One Out. Trends Microbiol. 2016; 24 (8): 637–48.
  2. O'Neill MB, Mortimer TD, Pepperell CS. Diversity of Mycobacterium tuberculosis across Evolutionary Scales. PLoS Pathog. 2015; 11 (11): e1005257.
  3. Vargas R, Freschi L, Marin M, Epperson LE, Smith M, Oussenko I, et al. In-host population dynamics of Mycobacterium tuberculosis complex during active disease. Elife. 2021; 10: e61805.
  4. McIvor A, Koornhof H, Kana BD. Relapse, re-infection and mixed infections in tuberculosis disease. Pathog Dis. 2017; 75 (3).
  5. Ye M, Yuan W, Molaeipour L, Azizian K, Ahmadi A, Kouhsari E. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2021; 20 (1): 73.
  6. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M et al. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol. 2014; 52 (7): 2422–9.
  7. Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019; 17 (8): 479–96.
  8. Ford C, Yusim K, Ioerger T, Feng S, Chase M, Greene M, et al. Mycobacterium tuberculosis–heterogeneity revealed through whole genome sequencing. Tuberculosis (Edinb). 2012; 92 (3): 194–201.
  9. Chen J, Huang F, Yin X, Gu D. Assessments of Different Methods for Testing Heteroresistance to Rifampicin in Tubercle Bacillus. J Nanosci Nanotechnol. 2018; 18 (12): 8414–8.
  10. Chen L, Zhang J, Zhang H. Heteroresistance of Mycobacterium tuberculosis Strains May Be Associated More Strongly With Poor Treatment Outcomes Than Within-Host Heterogeneity of M. tuberculosis Infection. J Infect Dis. 2016; 214 (8): 1286–7.
  11. Rigouts L, Miotto P, Schats M, Lempens P, Cabibbe AM, Galbiati S, et al. Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations. Sci Rep. 2019; 9 (1): 11760.
  12. Global tuberculosis report 2023. Geneva: World Health Organization, 2023; 75 p.
  13. Huo F, Ma Y, Li S, Xue Y, Shang Y, Dong L, et al. Specific gyrA gene mutations correlate with high prevalence of discordant levofloxacin resistance in Mycobacterium tuberculosis isolates from Beijing, China. J Mol Diagn. 2020; 22 (9): 1199–204.
  14. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019; 104 p.
  15. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019; 200 (10): e93–e142.
  16. Jouet A, Gaudin C, Badalato N, Allix-Béguec C, Duthoy S, Ferré A, et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. Eur Respir J. 2021; 57 (3): 2002338.
  17. Zhang X, Zhao B, Liu L, Zhu Y, Zhao Y, Jin Q. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J Clin Microbiol. 2012; 50 (4): 1471–4.
  18. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011; 55 (5): 2032–41.
  19. Baffoe-Bonnie A, Houpt ER, Turner L, Dodge D, Heysell SK. Drug-Susceptible and Multidrug-Resistant Mycobacterium tuberculosis in a Single Patient. Emerg Infect Dis. 2019; 25 (11): 2120–1.
  20. Andreevskaya SN, Smirnova TG, Chernousova LN, Larionova EE, Kiseleva EA, Ergeshov A. The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation. Bulletin of RSMU. 2022; (5): 15–22.
  21. Kodio O, Georges Togo AC, Sadio Sarro YD, Fane B, Diallo F, Somboro A. et al. Competitive fitness of Mycobacterium tuberculosis in vitro. Int J Mycobacteriol. 2019; 8 (3): 287–91.
  22. Aleshina ES, Drozdova EA, Romanenko NA. Kul'tivirovanie mikroorganizmov kak osnova biotehnologicheskogo processa: uchebnoe posobie. Orenburg: OOO IPK «Universitet», 2017; 191 s. Russian.
  23. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006; 312 (5782): 1944–6.
  24. Peddireddy V, Doddam SN, Ahmed N. Mycobacterial Dormancy Systems and Host Responses in Tuberculosis. Front Immunol. 2017; 8: 84.
  25. An Q, Lin R, Yang Q, Wang C, Wang D. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and metaanalysis. J Glob Antimicrob Resist. 2023; 34: 214–26.
  26. Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59 (5): 866–73.
  27. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014; 46 (3): 279–86.
  28. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 2004; 84 (1–2): 29–44.
  29. Mitchison DA, Coates AR. Predictive in vitro models of the sterilizing activity of anti-tuberculosis drugs. Curr Pharm Des. 2004; 10 (26): 3285–95.